Part 15 Public Hearing: Scientific Data and Information Related to the Residue of Carcinogenic Concern for the New Animal Drug Carbadox - Extension of Comment Period

If your email program has trouble displaying this email, view as a webpage. Part 15 Public Hearing: Scientific Data and Information Related to the Residue of Carcinogenic Concern for the New Animal Drug Carbadox Extension of Comment Period The FDA is extending the public comment period for the part 15 public hearing on "Scientific Data and Information Related to the Residue of Carcinogenic Concern for the New Animal Drug Carbadox." The agency is taking this action in response to a request for an extension to allow interested persons additional time to submit comments. The FDA is extending the comment period by 60 days, until June 10, 2022. You are subscribed to updates from FDA's Center for Veterinary Medicine.

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA